(PHG) Koninklijke Philips - Ratings and Ratios
Medical Imaging, Patient Monitoring, Home Healthcare, Personal Care
PHG EPS (Earnings per Share)
PHG Revenue
Description: PHG Koninklijke Philips October 14, 2025
Koninklijke Philips N.V. (PHG) is a Dutch-based health-technology group that serves North America, Greater China, and the rest of the world through three operating segments: Diagnosis & Treatment, Connected Care, and Personal Health.
In Diagnosis & Treatment, Philips supplies a full suite of imaging equipment-including MRI, X-ray, and detector-based spectral CT systems-as well as ultrasound platforms for cardiac, obstetric, and point-of-care use, plus integrated interventional X-ray suites and software that support minimally invasive coronary, peripheral vascular, and rhythm-management procedures.
The Connected Care segment delivers acute patient-management tools, emergency-care platforms, home-care monitoring, sleep-and-respiratory solutions, and vendor-agnostic software that enable clinicians to coordinate care across hospitals, clinics, and patients’ homes.
Personal Health focuses on consumer-facing products such as electric toothbrushes, infant-feeding devices, baby monitors, digital women’s-health apps, and grooming/beauty solutions, leveraging Philips’ brand equity in everyday health.
According to Philips’ FY2023 results, the company generated €20.4 billion in revenue, with an adjusted operating margin of roughly 13 %. The Connected Care segment grew 12 % YoY, driven by expanding tele-health adoption and higher demand for remote-monitoring devices, while Diagnosis & Treatment remained the largest revenue contributor but showed modest double-digit growth in its software-as-a-service offerings.
Key macro drivers for Philips include the global aging population (projected to reach 1.5 billion people over 65 by 2030), rising US Medicare and private-payer reimbursement rates for advanced imaging and remote-monitoring services, and the ongoing shift toward capital-efficient, subscription-based health-tech models that favor software-enabled hardware.
For a deeper quantitative assessment of Philips’ valuation and risk profile, you may find it useful to explore the company’s metrics on ValueRay.
PHG Stock Overview
| Market Cap in USD | 26,113m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1987-12-30 |
PHG Stock Ratings
| Growth Rating | 45.7% |
| Fundamental | 45.6% |
| Dividend Rating | 23.4% |
| Return 12m vs S&P 500 | -6.72% |
| Analyst Rating | 4.0 of 5 |
PHG Dividends
| Dividend Yield 12m | 3.43% |
| Yield on Cost 5y | 2.11% |
| Annual Growth 5y | -0.57% |
| Payout Consistency | 75.9% |
| Payout Ratio | 89.7% |
PHG Growth Ratios
| Growth Correlation 3m | 29.3% |
| Growth Correlation 12m | 43% |
| Growth Correlation 5y | -34.9% |
| CAGR 5y | 26.67% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.79 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.39 |
| Sharpe Ratio 12m | 1.12 |
| Alpha | -7.43 |
| Beta | 0.843 |
| Volatility | 32.79% |
| Current Volume | 696.3k |
| Average Volume 20d | 696.3k |
| Stop Loss | 27.3 (-3.1%) |
| Signal | 0.74 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (162.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -2.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.43% (prev 7.59%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.09b > Net Income 162.0m (YES >=105%, WARN >=100%) |
| Net Debt (6.60b) to EBITDA (2.21b) ratio: 2.99 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (956.7m) change vs 12m ago 1.58% (target <= -2.0% for YES) |
| Gross Margin 43.85% (prev 41.56%; Δ 2.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.94% (prev 61.52%; Δ 2.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.53 (EBITDA TTM 2.21b / Interest Expense TTM 323.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.35
| (A) 0.07 = (Total Current Assets 9.06b - Total Current Liabilities 7.20b) / Total Assets 26.38b |
| (B) 0.12 = Retained Earnings (Balance) 3.03b / Total Assets 26.38b |
| (C) 0.04 = EBIT TTM 1.14b / Avg Total Assets 27.93b |
| (D) 0.22 = Book Value of Equity 3.57b / Total Liabilities 15.97b |
| Total Rating: 1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 45.64
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 0.95% = 0.48 |
| 3. FCF Margin 1.56% = 0.39 |
| 4. Debt/Equity 0.81 = 2.18 |
| 5. Debt/Ebitda 2.99 = -1.76 |
| 6. ROIC - WACC (= -2.05)% = -2.56 |
| 7. RoE 1.41% = 0.12 |
| 8. Rev. Trend -20.17% = -1.51 |
| 9. EPS Trend -33.78% = -1.69 |
What is the price of PHG shares?
Over the past week, the price has changed by +3.11%, over one month by +1.22%, over three months by +5.86% and over the past year by +6.36%.
Is Koninklijke Philips a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHG is around 24.76 USD . This means that PHG is currently overvalued and has a potential downside of -12.11%.
Is PHG a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PHG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.3 | 18.3% |
| Analysts Target Price | 33.3 | 18.3% |
| ValueRay Target Price | 27.2 | -3.5% |
PHG Fundamental Data Overview November 05, 2025
P/E Trailing = 143.2105
P/E Forward = 14.5138
P/S = 1.4625
P/B = 2.1673
P/EG = 0.3632
Beta = 0.843
Revenue TTM = 17.86b EUR
EBIT TTM = 1.14b EUR
EBITDA TTM = 2.21b EUR
Long Term Debt = 7.18b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.24b EUR (from shortTermDebt, last quarter)
Debt = 8.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.60b EUR (from netDebt column, last quarter)
Enterprise Value = 29.29b EUR (22.68b + Debt 8.43b - CCE 1.82b)
Interest Coverage Ratio = 3.53 (Ebit TTM 1.14b / Interest Expense TTM 323.0m)
FCF Yield = 0.95% (FCF TTM 279.0m / Enterprise Value 29.29b)
FCF Margin = 1.56% (FCF TTM 279.0m / Revenue TTM 17.86b)
Net Margin = 0.91% (Net Income TTM 162.0m / Revenue TTM 17.86b)
Gross Margin = 43.85% ((Revenue TTM 17.86b - Cost of Revenue TTM 10.03b) / Revenue TTM)
Gross Margin QoQ = 46.36% (prev 45.13%)
Tobins Q-Ratio = 1.11 (Enterprise Value 29.29b / Total Assets 26.38b)
Interest Expense / Debt = 0.95% (Interest Expense 80.0m / Debt 8.43b)
Taxrate = 28.19% (95.0m / 337.0m)
NOPAT = 817.9m (EBIT 1.14b * (1 - 28.19%))
Current Ratio = 1.26 (Total Current Assets 9.06b / Total Current Liabilities 7.20b)
Debt / Equity = 0.81 (Debt 8.43b / totalStockholderEquity, last quarter 10.38b)
Debt / EBITDA = 2.99 (Net Debt 6.60b / EBITDA 2.21b)
Debt / FCF = 23.67 (Net Debt 6.60b / FCF TTM 279.0m)
Total Stockholder Equity = 11.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.61% (Net Income 162.0m / Total Assets 26.38b)
RoE = 1.41% (Net Income TTM 162.0m / Total Stockholder Equity 11.49b)
RoCE = 6.10% (EBIT 1.14b / Capital Employed (Equity 11.49b + L.T.Debt 7.18b))
RoIC = 4.78% (NOPAT 817.9m / Invested Capital 17.09b)
WACC = 6.83% (E(22.68b)/V(31.11b) * Re(9.12%) + D(8.43b)/V(31.11b) * Rd(0.95%) * (1-Tc(0.28)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.14%
[DCF Debug] Terminal Value 65.74% ; FCFE base≈589.0m ; Y1≈386.7m ; Y5≈176.8m
Fair Price DCF = 3.08 (DCF Value 2.93b / Shares Outstanding 950.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -33.78 | EPS CAGR: -62.67% | SUE: -4.0 | # QB: 0
Revenue Correlation: -20.17 | Revenue CAGR: 0.24% | SUE: 0.00 | # QB: 0
Additional Sources for PHG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle